Humanwell Healthcare (Group) Co., Ltd.

After a three-month hiatus, leading domestic anesthetics producer Humanwell Healthcare has officially been "acquired" by a state-backed entity. On January 15, the company announced that it had signed a restructuring investment agreement with Zhaoshang Innovation Technology Group Co., Ltd. and its management team. This collaboration involves an investment of ¥11.8 billion, positioning Zhaoshang Innovation as the new controlling shareholder, with a 23.70% stake in Humanwell Healthcare. The restructuring investment will be executed in two phases. The first phase, covering 60% of the investment, will be paid upon the approval of the restructuring plan by the Wuhan Intermediate People’s Court. The remaining 40% will be paid after the completion of stock and voting rights transfers. Once this restructuring plan is finalized, Humanwell Healthcare will officially transition to state-owned control, a move that has significantly boosted its stock price, reaching ¥23.6 per share and a market capitalization of ¥38.52 billion. A Shift in Leadership: Hope for the "Anesthetic King" Founded in 1993, Humanwell Healthcare was once the dominant force in the anesthetic drugs sector. However, it has faced unprecedented challenges due to its former major shareholder, Dandai Technology, being mired in a debt crisis. Previously, six potential restructuring investors had passed the initial review, including three state-owned enterprises and three large local state-owned enterprises. Dandai Technology’s 23.7% stake in Humanwell Healthcare is currently frozen due to judicial actions. The entry of Zhaoshang Innovation brings a glimmer of hope, with the investment structured in three parts: Direct acquisition of 6% of Humanwell Healthcare’s shares. Indirect acquisition of another 6% through a new limited partnership in the Donghu New Technology Development Zone, with Zhaoshang Innovation as the general partner. Trust plan acquiring 11.70% of shares, with all voting rights delegated to Zhaoshang Innovation. Zhaoshang Innovation is controlled by China Merchants Group, a significant state-owned enterprise headquartered in Hong Kong. In 2023, China Merchants Group reported revenues of ¥924.4 billion and a net profit of ¥191.1 billion, showcasing its robust financial standing. Strategic Investment Amid Market Challenges Zhaoshang Innovation's substantial investment indicates its strategic interest in Humanwell Healthcare's industry-leading position in the pharmaceutical sector. Humanwell Healthcare is one of the few companies capable of producing a full range of fentanyl products and has established a strong foothold in various segments, including anesthetics and steroid hormones. According to the latest data, Humanwell Healthcare holds a 25.9% market share in the anesthetics market, making it the leading player. Its products, including alfentanil and hydromorphone, have a 100% market share, illustrating its dominance. In the past five years, Humanwell Healthcare has invested ¥4.6 billion in research and development, reflecting a commitment to innovation. In 2023, R&D expenses surpassed ¥1 billion, with a 9.2% increase in the first three quarters of 2024. The company has received approval for 1 traditional Chinese medicine and 17 chemical drug products, indicating a robust pipeline for future growth. Despite these positive developments, challenges remain. The competitive landscape is fierce, and the company must ensure that its R&D investments yield proportional returns. The support from Zhaoshang Innovation may provide the necessary impetus for Humanwell Healthcare to navigate these challenges successfully and emerge stronger.   With Zhaoshang Innovation taking a controlling stake, Humanwell Healthcare's ownership issue has reached a significant resolution. This strategic investment from a state-owned entity sends positive signals to the market. However, the company still faces challenges related to market competition and R&D efficiency. Observers will be keen to see if Humanwell Healthcare can leverage this new partnership to overcome its obstacles and achieve a successful turnaround.

9月7日，由中国医药工业信息中心主办，中国医药工业研究总院指导，四川省经济和信息化厅承办，四川省医药行业协会智慧支持的“2024年（第41届）全国医药工业信息年会暨2023年度中国医药工业百强榜单发布会”在成都开幕。 大会同期发布了备受行业关注的2023年度中国医药工业百强企业。中国医药集团有限公司、华润医药控股有限公司、齐鲁制药集团有限公司位列前三甲。 1 中国医药集团有限公司 2华润医药控股有限公司 3齐鲁制药集团有限公司 4上海复星医药（集团）股份有限公司 5中国远大集团有限责任公司 6石药控股集团有限公司 7广州医药集团有限公司 8上海医药（集团）有限公司 9扬子江药业集团有限公司 10修正药业集团股份有限公司 11江苏恒瑞医药股份有限公司 12正大天晴药业集团股份有限公司 13诺和诺德（中国）制药有限公司 14拜耳医药保健有限公司 15四川科伦药业股份有限公司 16江西济民可信集团有限公司 17晖致制药（大连）有限公司 18阿斯利康制药有限公司 19长春高新技术产业（集团）股份有限公司 20威高集团有限公司 21山东步长制药股份有限公司 22新和成控股集团有限公司 23珠海联邦制药股份有限公司 24人福医药集团股份公司 25丽珠医药集团股份有限公司 26赛诺菲（中国）投资有限公司 27西安杨森制药有限公司 28北京诺华制药有限公司 29杭州默沙东制药有限公司 30石家庄以岭药业股份有限公司 31鲁南制药集团股份有限公司 32华北制药集团有限责任公司 33江苏济川控股集团有限公司 34深圳市东阳光实业发展有限公司 35江苏豪森药业集团有限公司 36普洛药业股份有限公司 37天津市医药集团有限公司 38上海罗氏制药有限公司 39浙江华海药业股份有限公司 40山东新华制药股份有限公司 41江苏鱼跃医疗设备股份有限公司 42沈阳三生制药有限责任公司 43天士力医药集团股份有限公司 44费森尤斯卡比（中国）投资有限公司 45云南白药集团股份有限公司 46成都倍特药业股份有限公司 47乐普（北京）医疗器械股份有限公司 48山东鲁抗医药股份有限公司 49信达生物制药（苏州）有限公司 50浙江康恩贝制药股份有限公司 51石家庄四药有限公司 52默克制药（江苏）有限公司 53葵花药业集团股份有限公司 54浙江海正药业股份有限公司 55浙江医药股份有限公司 56青峰医药集团有限公司 57深圳市海普瑞药业集团股份有限公司 58浙江九洲药业股份有限公司 59华兰生物工程股份有限公司 60哈药集团有限公司 61天津红日药业股份有限公司 62先声药业有限公司 63瑞阳制药股份有限公司 64江苏康缘药业股份有限公司 65东北制药集团股份有限公司 66北京泰德制药股份有限公司 67神威药业集团有限公司 68漳州片仔癀药业股份有限公司 69东富龙科技集团股份有限公司 70辰欣科技集团有限公司 71烟台绿叶医药控股（集团）有限公司 72上海创诺医药集团有限公司 73上海莱士血液制品股份有限公司 74四川好医生攀西药业有限责任公司 75江苏恩华药业股份有限公司 76楚天科技股份有限公司 77四川新绿色药业科技发展有限公司 78浙江仙琚制药股份有限公司 79悦康药业集团股份有限公司 80厦门万泰沧海生物技术有限公司 81成都康弘药业集团股份有限公司 82浙江京新药业股份有限公司 83健康元药业集团股份有限公司 84上海勃林格殷格翰药业有限公司 85玉溪沃森生物技术有限公司 86贵州健兴药业有限公司 87山东齐都药业有限公司 88仁和（集团）发展有限公司 89江苏苏中健康科技有限公司 90南京健友生化制药股份有限公司 91山东金城医药集团股份有限公司 92海思科医药集团股份有限公司 93朗致集团有限公司 94中国医药健康产业股份有限公司 95河南羚锐制药股份有限公司 96深圳信立泰药业股份有限公司 97烟台东诚药业集团股份有限公司 98山西亚宝投资集团有限公司 99卫材（中国）投资有限公司 100郑州安图生物工程股份有限公司 排名范围：按照工业和信息化部“2023年《中国医药统计年报》汇编工作的通知”要求，如期上报完整数据和相关材料的全部医药工业企业 指标依据：按2023年医药工业企业法人单位的主营业务收入前100位 排序数据来源：2023年《中国医药统计年报》

The latest release shows that Humanwell Healthcare has delivered remarkable results in the first half of 2024, demonstrating excellent market performance. Specifically, the company managed to achieve solid growth in total operating revenue, totaling RMB12.861 billion, an increase of 3.86% over the same period last year, marking the fourth consecutive year of good growth for Humanwell Healthcare. Despite some fluctuations in net profit, Humanwell Healthcare's core subsidiary, Yichang Humanwell, maintained strong growth momentum and achieved double-digit growth rates, providing strong support for the company's overall performance. As a leading pharmaceutical company in China, Humanwell Healthcare has been committed to the research and development, production and sales of pharmaceutical products since its establishment in 1993. Headquartered in Wuhan, Hubei Province, Humanwell Healthcare is a key player in China's pharmaceutical industry. Humanwell Healthcare's product line is rich and diverse, including many star products. Compound Cloloterol propionate tablet, as one of the company's core products, is an oral drug for type 2 diabetes, which has the effect of significantly reducing blood sugar and protecting islet function, and enjoys a high reputation in the field of diabetes treatment in China. Gastrodine capsule is a Chinese medicine preparation for the treatment of ischemic stroke sequelae, which can significantly improve the blood supply to the brain and promote the repair of nerve function, and is an important representative of the company in the field of Chinese medicine. In addition, as the company's main product in the field of respiratory treatment, trimebutin tablets can effectively improve the respiratory function of patients with chronic obstructive pulmonary disease (COPD), and occupy an important position in the domestic COPD treatment market. Humanwell Healthcare continues to consolidate and expand its market leadership in the key area of neurological medicine. The company's two star narcotic products - remifentanil hydrochloride for injection and sufentanil citrate injection, the performance of the national hospital market in 2023 is particularly eye-catching. The combined sales of these two products reached 6.778 billion yuan, accounting for more than 40% of the market share. Among them, remifentanil hydrochloride for injection is as high as 90.28% of the market share, sitting firmly on the throne of "anesthesia first", its market position is rock-solid. Humanwell Healthcare will continue to uphold the philosophy of continuous innovation and excellence to further consolidate its leading position in the field of anesthetics. At the same time, the company will also accelerate the research and development process of new product pipelines, actively expand other therapeutic areas, and continuously improve its overall competitive strength with a diversified product portfolio and strong research and development strength. We firmly believe that with the joint efforts of all employees, Humanwell Healthcare will be able to create even more brilliant results and bring even greater returns to shareholders.